Granzyme K Knockout Mice Exhibit Reduced Loss of Function with Age
A rising level of chronic inflammatory signaling in the absence of any provoking infection or injury is characteristic of aging, and a strong driver of tissue dysfunction. It arises from multiple mechanisms that maladaptively provoke the sensors and regulatory systems that control inflammation. These mechanisms include the presence of lingering senescent cells that secrete pro-inflammatory signals, the reactions of immune cells to the damage and metabolic waste they encounter in aged tissues, and forms of damage inside cells, such as mislocalized mitochondrial DNA, that triggers sensors evolved to detect pathogens. It would be hard to eliminate age-related inflammation without first eliminating a very large fraction of the cell and tissue damage that drives aging. A worthy goal, of course.
Despite the evident harms done by chronic inflammation, it is far from the only meaningful contribution to degenerative aging as a whole. It is a feature, a consequence of damage, a cause of further damage, but it doesn't act alone. Today's open access paper is an interesting demonstration of that point. The authors discovered that mice without active granzyme K signaling exhibit a slowed age-related deterioration of many measures of cell and tissue function. This occurs without any reduction in the chronic inflammation of aging, however, despite the fact that granzyme K is primarily secreted by T cells, is cytotoxic, and is known to engage with pro-inflammatory pathways. This study shows that granzyme K must be accelerating tissue aging via non-inflammatory mechanisms, which is an unexpected outcome.
Among the many systems affected during biological aging, the immune compartment undergoes some of the most striking and consequential changes. Within this compartment, CD8+ T cells stand out as arguably the most affected by the aging process, with severely diminished naive CD8+ T cells, and marked evidence of dysfunction across memory phenotype cells, including both virtual memory T (Tvm) cells and conventional memory T (Tmem) cells. Strikingly, recent studies demonstrate that aging of the immune system, and of T cells in particular, can actively precipitate systemic aging. Studies indicate that T cells mediate these processes in part via the production of pro-inflammatory mediators.
Within this aging context, granzyme K (GzmK), a trypsin-like serine protease produced predominantly by CD8+ T cells, but also by γδ T cells, natural killer (NK) cells, and macrophages, has emerged as a key molecule of interest. Unlike other granzyme family members, which are associated with cytotoxicity, GzmK appears to be primarily pro-inflammatory, able to drive inflammation by activating PAR-1 and PAR-2 signaling, inducing cytokine and chemokine expression, and enhancing endothelial and myeloid-cell activation. Further, it was recently shown to activate the complement pathway and induce cellular senescent phenotypes in vitro. Consistent with these functions, it is strongly associated with a variety of inflammatory diseases in humans.
We show that GzmK protein is substantially increased with age in mice, uniquely within the T cell compartment and predominantly within conventional memory CD8+ T cells. Using young and aged GzmK-deficient (GzmK-/-) mice, we investigate the role of GzmK in driving key hallmarks of immune and organismal aging. GzmK deficiency over a lifespan could not attenuate systemic inflammaging, as measured by increases in serum inflammatory cytokines such as IL-6 and MCP-1. Moreover, the elevation of C3a in the serum of aged mice was not reduced in the absence of GzmK. Indeed, the reversal of the aging serum proteomic profile in GzmK-/- mice appeared to reflect activity at the level of tissues, with reduced serum abundance of intracellular proteins, including mitochondrial proteins, indicative of cellular turnover, and tissue enzymes such as ALT, AST, and ALDOB, indicative of organ stress and dysfunction. Consistent with this, GzmK deficiency had no impact on immune aging, either at steady state or following challenge.
Collectively, these findings indicate that GzmK acts locally within tissues to drive age-associated decline, rather than systemically to promote inflammaging or immune dysfunction.